Ethyl 4-(4-formyl-3-thiophen-2-ylpyrazol-1-yl)benzoate | 694434-92-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: Ethyl 4-(4-formyl-3-thiophen-2-ylpyrazol-1-yl)benzoate
• CAS: 694434-92-9
• 化学式: C₁₇H₁₄N₂O₃S
• 分子量: 326.376
• InChiKey: QDGVGZJIGQJLGR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  23
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  89.4
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  Ethyl 4-(4-formyl-3-thiophen-2-ylpyrazol-1-yl)benzoate 在 lithium hydroxide 、 甲酸 、 盐酸羟胺 、 水 、 sodium formate 作用下， 以 四氢呋喃 为溶剂， 生成 4-(4-Cyano-3-thiophen-2-ylpyrazol-1-yl)benzoic acid
  参考文献：
  名称：

  NITROGENATED HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

  摘要：

  公开号：

  EP1932833B1
• 作为产物：
  描述：

  4-肼基苯甲酸 在 盐酸 、 三氯氧磷 作用下， 以 水 为溶剂， 反应 23.0h， 生成 Ethyl 4-(4-formyl-3-thiophen-2-ylpyrazol-1-yl)benzoate
  参考文献：
  名称：

  NITROGENATED HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

  摘要：

  公开号：

  EP1932833B1

文献信息

• US7947707B2
  申请人：——

  公开号：US7947707B2

  公开（公告）日：2011-05-24
• [EN] PYRAZOLE DERIVATIVES AS MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS<br/>[FR] COMPOSES ET COMPOSITIONS DE MODULATION
  申请人：CAREX SA

  公开号：WO2004043951A1

  公开（公告）日：2004-05-27

  The present invention relates to compounds, compositions and methods useful for modulating nuclear receptors activity in cells, and for treating and/or preventing various diseases and conditions mediated by said nuclear receptors, including metabolic or cell proliferative disorders. According to particular aspects, the present invention relates to compounds, compositions and methods useful for modulating activities of the Peroxisome Proliferator Activated Receptors (PPARs) and for treating and/or preventing various disease and conditions mediated by said nuclear receptors. More specifically, it relates to Peroxigome Proliferator Activated Receptor-gamma (PPAR-gamma) ligands, which are useful in the modulation of blood glucose levels and in the increase of insulin sensitivity in patients in need thereof. The properties of the compounds and compositions of the invention make these PPAR ligands particularly useful in the treatment of those diseases and conditions including diabetes, atherosclerosis, hyperglycemia, dyslipidemia, obesity, syndrome X, insulin resistance, hypertension, neuropathy, microvascular diseases (e.g. retinopathy, nephropathy), macrovascular diseases (e.g. myocardial infarction, stroke, heart failure) in mammals.